Cargando…

Sarcomas of the paranasal sinuses: An analysis of the SEER database

OBJECTIVE: To determine the demographics, treatment modalities, and overall survival of patients with sinonasal sarcoma. METHODS: All cases of primary sinonasal sarcomas diagnosed between the years of 2009 and 2014 were extracted from the National Cancer Institute's Surveillance, Epidemiology,...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Elaine, Radomski, Shannon, Harley, Earl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383302/
https://www.ncbi.nlm.nih.gov/pubmed/30828621
http://dx.doi.org/10.1002/lio2.245
_version_ 1783396819463569408
author Martin, Elaine
Radomski, Shannon
Harley, Earl
author_facet Martin, Elaine
Radomski, Shannon
Harley, Earl
author_sort Martin, Elaine
collection PubMed
description OBJECTIVE: To determine the demographics, treatment modalities, and overall survival of patients with sinonasal sarcoma. METHODS: All cases of primary sinonasal sarcomas diagnosed between the years of 2009 and 2014 were extracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Additional variables collected included age, gender, ethnicity, tumor histological subtype, tumor size, treatment modality, vitality status, and follow‐up time. Kaplan‐Meier survival curves were generated and overall survival was calculated. RESULTS: One hundred and four cases of sinonasal sarcoma were identified. The majority of patients were female (55%), white (76%), and non‐Hispanic (84%), and the mean age was 47 ± 22 years. The most common tumor sites were the maxillary sinus, followed by the ethmoid, sphenoid, and frontal sinus. Forty six percent of tumors were rhabdomyosarcoma type. Most patients (66%) had some type of surgery, 64% received radiation, and 58% received chemotherapy as part of their treatment. Overall 1‐ and 5‐year survival was 79% and 31%, respectively. There was no significant difference in survival based on patient gender, age, ethnicity, radiation, or chemotherapy treatment. CONCLUSIONS: This study adds to the current literature of sinonasal sarcomas and is the first to report in detail the surgical interventions performed as well as characteristics about lymph node spread, tumor histology, and treatment outcomes since the advent of radiation and chemotherapy. As these tumors are so rare, continued study of the demographics, tumor characteristics, and long‐term outcomes of this population is necessary to guide treatment modalities and strategies for otolaryngologists. LEVEL OF EVIDENCE: 2b
format Online
Article
Text
id pubmed-6383302
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-63833022019-03-01 Sarcomas of the paranasal sinuses: An analysis of the SEER database Martin, Elaine Radomski, Shannon Harley, Earl Laryngoscope Investig Otolaryngol Head and Neck, and Tumor Biology OBJECTIVE: To determine the demographics, treatment modalities, and overall survival of patients with sinonasal sarcoma. METHODS: All cases of primary sinonasal sarcomas diagnosed between the years of 2009 and 2014 were extracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Additional variables collected included age, gender, ethnicity, tumor histological subtype, tumor size, treatment modality, vitality status, and follow‐up time. Kaplan‐Meier survival curves were generated and overall survival was calculated. RESULTS: One hundred and four cases of sinonasal sarcoma were identified. The majority of patients were female (55%), white (76%), and non‐Hispanic (84%), and the mean age was 47 ± 22 years. The most common tumor sites were the maxillary sinus, followed by the ethmoid, sphenoid, and frontal sinus. Forty six percent of tumors were rhabdomyosarcoma type. Most patients (66%) had some type of surgery, 64% received radiation, and 58% received chemotherapy as part of their treatment. Overall 1‐ and 5‐year survival was 79% and 31%, respectively. There was no significant difference in survival based on patient gender, age, ethnicity, radiation, or chemotherapy treatment. CONCLUSIONS: This study adds to the current literature of sinonasal sarcomas and is the first to report in detail the surgical interventions performed as well as characteristics about lymph node spread, tumor histology, and treatment outcomes since the advent of radiation and chemotherapy. As these tumors are so rare, continued study of the demographics, tumor characteristics, and long‐term outcomes of this population is necessary to guide treatment modalities and strategies for otolaryngologists. LEVEL OF EVIDENCE: 2b John Wiley & Sons, Inc. 2019-01-15 /pmc/articles/PMC6383302/ /pubmed/30828621 http://dx.doi.org/10.1002/lio2.245 Text en © 2019 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals, Inc. on behalf of The Triological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Head and Neck, and Tumor Biology
Martin, Elaine
Radomski, Shannon
Harley, Earl
Sarcomas of the paranasal sinuses: An analysis of the SEER database
title Sarcomas of the paranasal sinuses: An analysis of the SEER database
title_full Sarcomas of the paranasal sinuses: An analysis of the SEER database
title_fullStr Sarcomas of the paranasal sinuses: An analysis of the SEER database
title_full_unstemmed Sarcomas of the paranasal sinuses: An analysis of the SEER database
title_short Sarcomas of the paranasal sinuses: An analysis of the SEER database
title_sort sarcomas of the paranasal sinuses: an analysis of the seer database
topic Head and Neck, and Tumor Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383302/
https://www.ncbi.nlm.nih.gov/pubmed/30828621
http://dx.doi.org/10.1002/lio2.245
work_keys_str_mv AT martinelaine sarcomasoftheparanasalsinusesananalysisoftheseerdatabase
AT radomskishannon sarcomasoftheparanasalsinusesananalysisoftheseerdatabase
AT harleyearl sarcomasoftheparanasalsinusesananalysisoftheseerdatabase